Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.
Repository Usage Stats
Notch signaling is implicated in prostate cancer progression and docetaxel resistance. Cui and colleagues describe the additive efficacy and mechanisms of a γ-secretase inhibitor, PF-03084014, and docetaxel in preclinical models of prostate cancer, suggesting the need for further clinical development of Notch pathway modulators in men with metastatic prostate cancer.
SubjectAmyloid Precursor Protein Secretases
Antineoplastic Combined Chemotherapy Protocols
Published Version (Please cite this version)10.1158/1078-0432.CCR-15-1613
Publication InfoZhang, T; & Armstrong, AJ (2015). Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch. Clin Cancer Res, 21(20). pp. 4505-4507. 10.1158/1078-0432.CCR-15-1613. Retrieved from http://hdl.handle.net/10161/10916.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record